<SEC-DOCUMENT>0001564590-20-002921.txt : 20200323
<SEC-HEADER>0001564590-20-002921.hdr.sgml : 20200323
<ACCEPTANCE-DATETIME>20200131160517
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001564590-20-002921
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-corresp.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000001.jpg" title="" alt="" style="width:832px;height:122px;"></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:18pt;line-height:15pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VIA EDGAR </p>
<p style="margin-bottom:12pt;margin-top:18pt;line-height:15pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Securities and Exchange Commission</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Division of Corporation Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office of Life Sciences</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100 F Street, N.E. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:&#160;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sasha Parikh</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rolf Sundwall</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RE:&#160;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Form 10-K for the Year Ended December 31, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Filed February 27, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">File No. 001-36740</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="zzmpFIXED_FirmName"></a>FibroGen, Inc. (&#8220;<font style="font-weight:bold;font-style:italic;">FibroGen</font>&#8221; or the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">we</font>&#8221;) is submitting this letter via electronic submission in response to a letter (the &#8220;<font style="font-weight:bold;font-style:italic;">Comment Letter</font>&#8221;), dated December 20, 2019, from the Division of Corporation Finance, Office of Life Sciences, of the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;font-style:italic;">Commission</font>&#8221;) with respect to the Company&#8217;s Form 10-K for the year ending December 31, 2018 (the &#8220;<font style="font-weight:bold;font-style:italic;">2018 10-K</font>&#8221;), filed on February 27, 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Commission&#8217;s convenience, we have incorporated your comments into this response letter in italics. Capitalized terms used in this letter but otherwise not defined herein shall have the meanings ascribed to such terms in the 2018 10-K. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ITEM 1. BUSINESS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PAMREVLUMAB FOR THE TREATMENT OF FIBROSIS AND CANCER</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Clinical Development of Pamrevlumab, page 28</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">1. <font style="font-weight:normal;">We note your response to prior comment 1; however, we do not agree that the identity of a serious adverse event (SAE) determined to be possibly related to Pamrevlumab is immaterial to investors. Accordingly, please provide us proposed disclosure for use in future filings that identifies all such events. With reference to the third paragraph on page 33 of your Form 10-K, please also tell us whether any of the SAEs observed in the pamrevlumab arm of Study 069 were determined to be related to, or possibly related to, Pamrevlumab. If so, please include such information in your proposed disclosure.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000002.jpg" title="" alt="" style="width:814px;height:58px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000001.jpg" title="" alt="" style="width:832px;height:122px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Response:</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company acknowledges the Commission&#8217;s comment and appreciates the discussion via telephone on January 6, 2020. Further to our discussion, we believe that the serious adverse events (&#8220;<font style="font-weight:bold;font-style:italic;">SAEs</font>&#8221;) that a principal investigator deems &#8220;possibly related to study treatment&#8221; are not categorically material to an investor&#8217;s decision to buy or sell the Company&#8217;s stock, as discussed further below. However, we hope that our new proposal of disclosing the most common serious adverse events, which is typical of clinical trial results disclosure, and when applicable, other material safety information, will satisfy the Commission&#8217;s request for more adverse event disclosure.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designation of &#8220;possibly related to study treatment&#8221; by one clinical site&#8217;s principal investigator does not mean there is a causal relationship between our study drug and that serious adverse event. Rather it means that, given the information in his/her possession, the investigator cannot rule out the event as unrelated to the study drug in that one instance. It is important to note that the individual investigator does not have access to the overall study dataset or complete information about the study drug across other sites, trials or indications of study. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Food and Drug Administration (&#8220;<font style="font-weight:bold;font-style:italic;">FDA</font>&#8221;) itself does not deem such an investigator assessment a relevant consideration for serious adverse event reporting.&nbsp;&nbsp;Pursuant to 21 C.F.R. &#167;312.32(c)(1)(i) of the FDA regulations, the sponsor has the responsibility to submit IND safety reports to the FDA for adverse reactions that are not only serious but also unexpected (SUSARs), and <font style="font-style:italic;">only</font> if there is evidence to suggest a causal relationship between the drug and the adverse event. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon evaluation of these adverse events in the pamrevlumab studies, there was no evidence of a causal relationship between the drug and the events, and thus of materiality to investors. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even though a statement regarding safety may be included in disclosure for early stage studies, these statements may not remain relevant as a product candidate progresses through development.&nbsp;&nbsp;With pamrevlumab, the events designated as &#8220;possibly related to study treatment&#8221; by the investigator in these studies</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) did not lead to modification of the study design or drug administration during the study,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) did not impair the continuation of the clinical study under the IND on file with FDA, </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) did not impede the progression of pamrevlumab to subsequent stages of clinical development (pamrevlumab is currently in Phase 3 clinical trials for both IPF and pancreatic cancer), and </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) did not (and does not) impact the chances of U.S. regulatory approval of the study drug. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000002.jpg" title="" alt="" style="width:814px;height:58px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000001.jpg" title="" alt="" style="width:832px;height:122px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company therefore </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believes</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that disclosing these events in the context of an investigational drug that has </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">now </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been dosed to over </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> human subjects across 1</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trials globally would not help, and could confuse, an investor&#8217;s understanding of the value of the product candidate and the results of the Company&#8217;s clinical development. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We performed an analysis of disclosure practices in our industry, and we believe it is quite rare for companies to report events that are deemed possibly related only by an investigator.&nbsp;&nbsp;We searched biotechnology<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> company Form S-1s and Form 10-Ks that had the words &#8220;possibly related&#8221; within 75 words of &#8220;adverse event&#8221;. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the over 25,000 filings searched, only 245 filings met the search criteria, of which only 50 results (in 23 companies<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>) appeared in filings since 2016.&nbsp;&nbsp;Of these, only five companies reported adverse events deemed possibly related by a clinical investigator. One company reported a possibly related event that caused a death and the drug in question was placed on (and remains on) clinical hold. The second company reported a possibly related event as part of an 18-subject clinical trial. The other three companies removed the disclosure surrounding the possibly related event or study from their subsequent disclosures. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, despite the fact that almost all trials have events that are deemed possibly related by investigators (and pamrevlumab is being studied in fatal conditions with unmet medical need and significant, serious underlying co-morbidities), the vast majority of companies appear to not discuss them in their periodic reports.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Proposed Disclosure:<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the most typical and relevant disclosure for early-stage clinical trials is listing the most common serious adverse events reported by patients in each study, and whether there have been material safety issues, which may include discussion of safety signals. Unlike a designation of &#8220;possibly related to study treatment&#8221; by one clinical site&#8217;s principal investigator, a safety signal is a serious adverse event that, after investigation, and based on its severity, uniqueness or frequency across aggregated data, the Company believes there is a sufficient likelihood that there is a causal relationship between it and an investigational drug. </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Industry Codes used in the search were:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2833 &#8211; Medicinal Chemicals &amp; Botanical Products</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2834 &#8211; Pharmaceutical Preparations</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2835 &#8211; In Vitro &amp; In Vivo Diagnostic Substances</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2836 &#8211; Biological Products, (No Diagnostic Substances)</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.62%;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Eighteen of these 23 companies described adverse events that they (i.e. the sponsor) deemed possibly related to the study drug, as we believe is the more relevant disclosure, should that determination be made.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000002.jpg" title="" alt="" style="width:814px;height:58px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000001.jpg" title="" alt="" style="width:832px;height:122px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, the Company proposes to </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">further </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modify the applicable language in the Company&#8217;s next Form 10-K for the year-ending 2019 to </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">add </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the most c</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon adverse events for each trial. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are samples of the proposed disclosure across the referenced pamrevlumab clinical trials:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">Page 31 - Study 049 &#8211; Open-label Phase 2 trial of pamrevlumab in idiopathic pulmonary fibrosis (&#8220;IPF&#8221;)</p>
<p style="margin-top:13pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Eighty-nine patients had at least one adverse event. The most common reported serious adverse events were cough, fatigue, shortness of breath, upper respiratory tract infection, sore throat, bronchitis, nausea, dizziness, and urinary tract infection. No safety signal was identified in this study and adverse events observed to date are consistent with typical conditions observed in this patient population.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;">Page 34 - Study 028 &#8211; Open-label dose finding trial of pamrevlumab combined with gemcitabine plus erlotinib in patients with previously untreated locally advanced (stage 3) or metastatic (stage 4) pancreatic cancer</p>
<p style="margin-top:13pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;In the study, the majority of adverse events were mild to moderate, and were consistent with those observed for erlotinib plus gemcitabine treatment without pamrevlumab. We did not identify any evolving dose-dependent pattern or safety signal, and higher doses of pamrevlumab were not associated with higher numbers of SAEs or greater severity of the SAEs observed. The most common reported serious adverse events were disease progression, cholangitis and pulmonary embolism.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Phase 1/2 trial (069) in patients with inoperable locally advanced pancreatic cancer (page 33 of the 2018 10-K), we propose to modify the applicable language in the Company&#8217;s next Form 10-K for the year-ending 2019 to:</p>
<p style="margin-top:13pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;No increase in serious adverse events was observed in the pamrevlumab arm and no delay in wound healing was observed post-surgery. In addition, no safety signal was identified in this study and there were no serious adverse events occurring in more than one subject.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company appreciates the Commission&#8217;s comments on this topic and believes the proposed disclosures above will provide more relevant, informative and less confusing disclosure for investors that is also more consistent with what similar companies disclose regarding safety of drug candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000002.jpg" title="" alt="" style="width:814px;height:58px;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000001.jpg" title="" alt="" style="width:832px;height:122px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please contact me at (415) 978-1522 with any questions or further comments regarding our responses to the Commission&#8217;s comments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ John Alden</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Alden</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Legal</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11pt;">Pat Cotroneo, FibroGen, Inc.<br />Michael Lowenstein, FibroGen, Inc.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11pt;">Michael Tenta, Cooley LLP </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Greg Vlahos, PricewaterhouseCoopers LLP</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr5zaktcv1se000002.jpg" title="" alt="" style="width:814px;height:58px;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gr5zaktcv1se000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gr5zaktcv1se000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V"?8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"M?:C9Z;"LM[<QP1LP16=L9)["K-8EVD^HZV=.O=(BF
MTI(Q,L[L&!D!X&/SXY_6ML  8 P!3:L9PDY-]@HHHI&@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-7(^0 ?NK4'^&,?^S=3_ #N:*[#4-;@=BQCO0RY/16B0@?SI[+0B4K-)]37
M   & .@I:**@T*.L-?+I<W]FR0I>' B,WW<DCCZ^GO5BT$ZV<(N?+\\(!)Y?
MW=V.<>V:XCQF[:IXMT#0XV./,^T2@'MG^8"M^==[5M6BCGI5.>K.VT;+]0HH
MHJ#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA)+K>C[IIY(5#+##@Y$A]?;TW>M=1X,T_3UTF/6()WO;O4$$D][-_K'/=?\
M9 (QM'3%:FDZ)8:+IWV&S@ B.3(7^9I2>K,>Y-<?X:G3P=XHU#PQ>3".PFS=
MZ?)(V%"G[R9/I@_]\D]Z+WC9%6L[L]!K&L#L\4:Q'_>CMY1SUR&7_P!E%9.H
M?$C0;:?[-8O/JMV3A8;&,R9/UZ'\,UA?:O&NN>(V:TM8-!,]HHS<D22>6CGD
M#'!R_0@4*+L[D5'K%KH_T9Z//<06L+37$T<,2_>>1@JC\37*WOQ(T"WG%M9/
M<:I<DX$5C$9"?QX!_ FJT'PUL[B9;CQ!J=]K-P.TTA6,?10<C\\5N7Z6'A;P
MW?7%A:6]JL4)*B) N6Z+G'7DBDE&]MRY2Y8N3T2.;\+.==\?:OK11A%;J(8@
MW8]/Y*?^^J] KDOASIYLO"D<SC]Y=R-,<]<=!^@S^-=;14?O670Y\#%JBI2W
MEJ_GJ%%%%0=84444 %%%% !17BWQ,\2:UIGC![:QU2ZMX1 C>7'(0,G.:X[_
M (33Q-_T';__ +_&ME1;5R'42=CZ:HKYE_X33Q-_T';_ /[_ !H_X33Q-_T'
M;_\ [_&G[!]Q>T1]-45\R_\ ":>)O^@[?_\ ?XT?\)IXF_Z#M_\ ]_C1[!]P
M]HCZ:HKYE_X33Q-_T';_ /[_ !H_X33Q-_T';_\ [_&CV#[A[1'TU17S+_PF
MGB;_ *#M_P#]_C71>!/%.O7_ (UTVUN]6NYH)'8/&\I(;Y&/(I.BTK@JB;/>
M***\E\>?$Z[L]1FTG0F6,P-LFNBH8[AU50>!CH3Z]/4YQBY.R+;2W/6J*^;+
M?Q]XIMY_.76KESG)60AU/X$8KV/P'XW3Q;921SQK%J-N 947[K@]&7^H[?C5
M2I.*N3&:9V%%%>9?%W6M3T?^Q_[.OI[7S?/\SRG*[L>7C/YG\ZF,>9V*;LKG
MIM%?,O\ PFGB;_H.W_\ W^-=C\,_$FM:GXP2VOM4NKB$P.WER2$C(QBM'1:5
MR543=CVFBBBL2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **S]8UO3M!LFN]2ND@B'3/WF/HHZDUY%XB^+V
MI7K-#HD0L;?IYS@-*W]%_7ZU<82EL2Y)'L]S>6UE%YMW<PP1CJ\KA1^9KGKK
MXA^$[0D2:S"Q_P"F2M)^J@BOG:[O;N_G,]Y<S7$IZO*Y8_F:@K94%U9#J/H?
M0G_"U/"7_/\ R_\ @._^%6;;XC^$KD@+K$:,>TL;IC\2,5\Y44_81%[1GU=9
MZC8ZC'YEE>6]RG]Z&0./TJS7R9!<36LRS6\TD4J\J\;%6'T(KNO#_P 5];TM
MEBU'&I6PX_>'$JCV;O\ CGZU$J#6Q2J+J>\T5C^'_$^E>)K3S].N-S+_ *R%
M^)(_J/ZCBMBL6FMS0****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCKNOA)_R/,?_ %[R?TKA:[KX2?\ (\Q_]>\G]*Z9_"S&.Y[[1117$= 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MSWB[Q=9>$]-\Z;$EU("(+<'ESZGT4=S6GK&JVVB:3<:C>-MA@3<<=6/8#W)P
M*^:=?UR\\1:O-J-Z^7D.%0'Y8U[*/8?_ %ZUIT^9Z[$3E836]=U#Q!J#7NHS
MF60\*O14'HH["LVBG1QO+(L<:,[L<*JC))] *Z]C$;17K'A7X1>;''>>(G9
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MZ?7%15BFKL<&TSWJBBBN0W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2M8[3PEI<<0P&MTD/U<;C^IK23]RZZG TJF,C%_85_F]OP-FBBBN<]$****
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M[%;@]>&!%=!_PL[QA_T&/_):'_XBLZE-R=T5&:2L?1-%?.W_  L[QA_T&/\
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M5=5/X48R^(UK3Q'J-CH%UHUM+Y5M=2!YBN=S#&-N?0]_7Z5DT5[!X%^&%O\
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M4<=^:FJG8:78Z6)A96Z0^=(9)-O\3&KE2[=#>/-;WMSP+XM_\CS)_P!>\?\
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M]SC[O 'K@_A6!176U=6,5H?0G_"U/"7_ #_R_P#@._\ A1_PM3PE_P _\O\
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M2C3"<1F[F;CB*SF;K]%Q7&?VPNC?$QKR.PO_ ++K-OL,30&-GF3NH;&>,?\
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MN=U\)/\ D>8_^O>3^E>^UX%\)/\ D>8_^O>3^E>^USUOB-:>P4445D6%%%%
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MSA\1Z[1117&;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS[D<D3R&U^"<A<&[UM0H/*Q6^2?Q)X_*NNT;X9^&]'993:M>SKR'NCN _P"
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MT57MIBY(G$Z1\+/#6F,LDT,E_*O.;ELKG_=& ?QS79Q11P1+%%&L<:#"H@P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU!R5)'1,_P!3^@%=I-#'<0O#-&LD3@JZ.,A@>Q%$,,=O!'!"@2.-0B*.@ X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-G:=N-V.,]*6B@
M#*T./4C;O<:S;VD=^S%=T'.8P<J"?Q/&?US6K113;NR81Y8VW"BBBD4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gr5zaktcv1se000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gr5zaktcv1se000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "V"?8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ2ZQICZA_9ZZC9M>Y(
M^S"=?,R!D_+G/3FB^UC3-,=$O]1L[1G&5$\ZQEA[9/-.S"Z+M%%%( HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*HW6M:58S"&\U.SMY3T2:=4/Y$U=5E=0RD,I&00>"* %HJE?:QIFF.B7^HV=
MHSC*B>=8RP]LGFKM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?/EHGB_2_%MQKJ>'+V\NVDD*O<V,K*"3]X8QVX';!KZ#HJX3Y;Z$RCS'
MS=XWUO7];N[237]+^P21HRQ+]GDBW GDX<G/X5ZII-[XB\8>%=>L]<TK[!.\
M)CMP;>2+>2IY^<G."!TJSXW\ _\ "8W=I/\ VG]C^SHR;?(\S=DY_O#%=I5R
MJ)Q5D1&#3=SR#X.Z[;62W^B7DJP3-+YT2R';N.-K#GOP./KZ4?&+7;:]6PT2
MSE6>99?.E6,[MIQM4<=^3Q]/6NB\3_"O2O$%])?V]Q)874IW2%$#H[?WMN1S
MZX-'ACX5Z5X?OH[^XN)+^ZB.Z,N@1$;^]MR>?3)JN:'-SBY96Y3J=!TP:?X9
MT_39T5C%:I%*I ()V_-QZ9S7F?Q'\.>$?#>G&>"Q*ZC=$K!"DS!%]7VYZ#TZ
M9([9KV"N UKX:/XA\4?VOJ>M&6 .,6BVVT",'A V_P#,X[GI6=.5I7;+G&ZL
MD9OPD\(_8[/_ (2&\C_?W"E;53_!'W;ZMV]OK7J--1%C1410J*,*H& !3JF<
MG)W8XQY58*\1^"G_ ",6H_\ 7I_[.M>W5Q'@KX>_\(?J-Q=_VI]K\Z+RMOV?
MR\<@YSN/I50DE%IBDFY)G':?_P G O\ ]=YO_1#4?&W_ )"ND_\ 7!__ $(5
MVEOX!\CX@GQ5_:>[+N_V;R,?>0I][=[YZ4>-_ /_  F-W:3_ -I_8_LZ,FWR
M/,W9.?[PQ6BG'G3\B'%\K1%\6O\ D0Y_^N\?\ZR-*_Y(!)_U[3_^CGKM/%OA
MW_A*=!DTO[5]EWNK^9Y>_&#GID?SJG:^#_LW@!O"WV_=F.2/[3Y./O.6SMW=
MLXZU"DE%+S*<7S-^1@?!91_PB%XV!N-^X)_[9Q_XUSOC%0/C7HY  )GLR??Y
MQ7HW@OPK_P (AH\VG_;?M?F7!G\SRO+QE57&,G^[^M9VL^ ?[7\:V?B+^T_*
M^S/"_P!G\C=N\ML_>W#&?I5*<>=L3B^5(Y3XW6TYDTBZP3;@21Y[*QP?U _2
MO3-&U?3-3T:&[T^>'[*(UX##]T,?=;T(J?5=*LM:TZ6POX%FMY1\RGL>Q![$
M>M>;7/P2LGN-UMK4\4.?N20!VQ_O C^52G&44F[6&U)2NC%O+B#7?C;:3:,0
MZ)<1&26/E7V %VSZ8!&?:I_C;_R%=)_ZX/\ ^A"O1/"W@G2?"<;FS5Y;J0;9
M+B4@N1Z#' '^3FL_QOX!_P"$QN[2?^T_L?V=&3;Y'F;LG/\ >&*I5(\Z[(EP
M?*^[-+QGH6E:]H1@U:Z%I'&X>.X+!?+;H.O'.<8KS?5O#GBSX?Z6VHZ;XD,M
MA"R@QY(QD@#$;94\FO3?%/A6R\6:<EI>23Q>6V^-XGQM/N.A_$?3%<>OP?20
M1PWOB.^GLXR-L 7&WZ9) _*E3DDM6.<6WHCK/!.OS>)/"UKJ-S&J3L623:."
M5.,CZUT-5--TVTTC3H+"RB$5O"NU%!S_ /K)/-671)8VCD4,C JRD9!![5D[
M7T-%>VIB6'C#P_JM_<V%MJ,#S0-M96. _KM)^\.W%>:_%RU\-PQVKZ>+5-6:
M7]ZEOCF/!R6 XSG&#U/-;NK_  :TB\N'FTZ]FL-YSY902HOT&0<?C3M'^#FC
MV-Q'/J%Y-?E#D1[!'&WU&22/QK:+A%\R9G)2DK-'1_#X7 \!:/\ :L^9Y/&?
M[FX[/_'=M>=_!1U36M4B9@)&@4A2>3AN>/QKVA55$5$4*JC  & !7FNJ_!ZS
MN]5DO;#5IK%9'+F,1;]N>H4[@0.OK4QDGS)Z7'*+T:Z$/QK.=#TS'_/RW_H-
M=QX118_!NB!%"@V,)P/4H"?U-8.M_#M=7\+Z5HB:F8%T_I*T&\OQCIN&*ZO2
M;'^R]'L=/\SS?LMO'!YFW;NVJ%SCMG%*37(DAI/F;/$/%5E<Q?%R9)-2?2S<
MR*T5Z"1L5DP#D$$#.5Z^M=1>>!/$-K92W%Y\0;N.U5"9'DDDV[??YZ[;Q-X2
MTKQ7:I%J$;"2//E3QG#IG^8]C7%_\*:CD=([CQ%=RV<?W(?*P5^A+$#\JT51
M-+6Q#@TWH:O@'PG_ &'HVHO::Q#?PZA&IADB3:JD!AGJ?4?3%>9>"-%U"_U:
M]TRV\03Z)>I@&-&93*5)!'RL.5].>IKWC1-#L/#VF)8:=#Y<*G)).6=CU8GN
M:Y_Q/\.-(\279O@\ME?'!::'&'(Z$CU]Q@U,:FKOU&X:*W0Y'6_ NH0VT4.N
M>/W\B>0*D=VSE6;MPSX_'M78-HTF@_"N_P!*>X%T\&G7($JKC<"KD<<] 0/P
MK$L_@]9_;%N-8UBZU'!'RE=FX>A.6./H17HGV2W%G]C$*"V\ORO+ PH7&,?3
M%*<]E>XXQ\CS/X)R)_9&J1[U\P3JQ7/.-O7]*]-N+FWM+=KBYGBA@09:61PJ
MJ/<GBO,I_@M:_:W>TUNX@MWR#$80S;3VW;AQ]15KXM7@TSP1:Z6C9-Q(D9SW
M1!DG\PM.24YZ/<(MQCKT/0+._L]1@\^QNX+J$-M\R"0.N?3([U8KG_!.D#1/
M!^G697$IB$LO^^WS'\LX_"N@K)V3T+6QB7WB[0]-UJ'2;O4(HKN1<X8X5/0,
MW0$]L_U&>?\ B)!X7F\,WES??8_MGE,;65"OFM)CY0,<D9QGMBIO$_PST;Q)
M=M>AY;.\?EY(L%7/J5/?W&*Y^T^"5E'+F\UJ>://W8H!&?S);^5:1Y%9W(ES
M/2PWX,230:+K4\N?L:2(RX_O!27_ $V5GZ1JGBOXD:K?"UULZ39V^&$<)*LH
M).T?+@L>.3G^=>M:9I5CH^G1V%C;K#;1C 0<Y]2?4GU-<+>_".S_ +2:\T?5
M[K2][9*1KNVCN%((('US5*<7)MB<6DD>>?$'0;GP_>V=K=>()M6E=&DVR@@Q
M#('0LW7'MTKNOC9_R ],_P"OEO\ T&I=2^#MG>6ULEOJTT=PC.T]S/%YKSD[
M<?Q# &#CKUKH_&W@_P#X3&QM;;[?]D\B0R;O)\S=D8QC<*?M(WCKL+D=F:'A
M)0O@W1 H 'V" \>Z"O+OA:H7XEZTJ@!1!. !V_?)7KNDV/\ 9>CV.G^9YOV6
MWC@\S;MW;5"YQVSBN7\+^ ?^$;\37VL_VG]H^U)(GD^1LV[G5NNXYQMQTJ%)
M6EYE.+NCM*\Y^-'_ ")UI_V$$_\ 1<E>C5SGC3PK_P )?H\.G_;?LGEW G\S
MRO,SA67&,C^]^E3!I2394TW&R,CP'X=T2\\$:7<76C:?/,\9+R2VJ,S?,>I(
MR:ZJST+1]/G\^RTJQMIL8\R&W1&QZ9 S4?AW1_[ \/V>E^?Y_P!G4KYNS;NR
M2>F3CKZUJ4I2;;"*LCQ;QLBR?&?2(W4,C36@93T(+BO::XO6? /]K^-;/Q%_
M:?E?9GA?[/Y&[=Y;9^]N&,_2NTJIR32L**:;/'IO$/B3QOXTN]$TC5!I=G!Y
MF&0[6*J=I;(Y))/0$8'TS6)\0/#-]X>L+1K_ ,47&IR3RDBWFW<8!R_+G.,X
MZ=Z[W7OA98ZIJTFJ:=J$^F74C%W,:[EW'JP&003SGFJU[\(K6\TWRFUBY?4&
ME5WO;A/-8J PV ;A@$D'J>E:QG%-69FX2:=ROXO_ .2):7_U[6?_ *"M=!\+
ME ^'>ED  L92??\ >O5C6/!_]J^"+7PY]O\ *\B.&/[1Y.[=Y8 SMW#&<>M:
M/A?0_P#A&_#EKI/VC[1]GW_O=FS=N=FZ9./O8ZUFY+DMYEJ+YK^1Y;IRA?V@
M7"@ >?,>/^N#5%JD\6B?'$7NK?+:F82!V' 5H]JM]%;'_?-=U;^ ?(^()\5?
MVGNR[O\ 9O(Q]Y"GWMWOGI6MXG\(:7XKM4BOT998\^5/$<.GM[CV-5[2-UZ6
M)Y';YFG/JNGVMHEW/>V\=NY 25I %;)P,'O7G7QL_P"0'I?_ %\M_P"@U%#\
M$K);G=/K4[P9^XD 5O\ OK)'Z5TOBCP%%X@T+3M*@OWM(;$_(SH9BPVXP<L*
MF/)&2:93YI1:L26^EZ?K'POTZSU.3RK1M-@9Y=P7R\1J=V3P,8KAKOP1XA\*
M:5/JOA[Q/YEC%&;@JKE R 9R!DJQQ^=>C7/A2TO_  A;>';V:5X88(XO-B8Q
MDE% #8Y';.#D5R ^#X\O[,?$M[]ASG[.$XZ_[V/TIPDEU%*+?0?HGB#4_&?P
MRUQ)U#W\44D.^-<>:-N>@[GD<52^#&JZ=%IU[IKRQQW[W'FJ&(!D3:  /7!!
MX]Z]%T'0+#PWI::?IT;+$I+,SG+.QZL3ZUR?B+X3Z/K5Y)>6D\FGSRDLX1 \
M98]]O&/P-'-%WCL@Y9*S.V34+.2^>Q2ZA:ZC3>\(<%U7.,D5XQX3NK?0?BWJ
M:ZRZQ/(\\:2RG 5V<,&SVRN>?]JNT\+?"^P\-ZE'J+W]Q=740.S \M!D8.0"
M2?IG%:?BOP'I/BPK-<>9;WB+M6XAQDCT8'J/U]Z47&+:Z,;4FKEOQ;JVFZ=X
M7OI+^6(Q2V[HD989F)4@!1WS_P#7KB?@E;7":7JMR^1;RRQI'D<;E!W'_P >
M7\J6S^"=A'<A[S6)YX0<^7'"(R1Z$Y/\A7I5A86NEV,5E90+#;Q#:B+T'^?6
MAN*CRK6X)-RNR.76-,AOEL9=1M([QB MN\ZB0D],+G/-7:\<\(Q?\)/\7=4U
MEP&@M'=T/7./W<?_ (Z,_A7L=3./*[%1E?4R_$>E?VYX<O\ 300K7$)5">@;
MJN?Q KR#X;^*D\):I>Z+K0:VAEDY9Q_J91P=WL?7V%>YUS'B;P'HOBD^==1/
M#=@8%S 0&(]#V;\>:<)))QEL*47>Z-IM7TU+4W3:A:"W R9?.7;CZYQ63H7C
MG0O$.H3V-C=$SQD[5D7;YJC^)<]1^OM7%?\ "D+?S\_V[+Y.?N?9AN_[ZW8_
M2NKT_P  Z?HNAWMEI$K07EW$8FOI5\R0 ]<#C'X8[=<4-02W!.=]CR;79M3\
M>>/KI]'@^TM#Q;KE0!$AQGYCC!)SS_>KI+FW^+MW:RVUQ&)(9D,<B'[)AE(P
M1^5=GX(\!P^#C=R?;?MD]QM7S/*\O8H[8W'J?Y"NOJY54M$M$3&F]VSP7X>7
MUWX2\>MI&I(8/M)%O-&S [7ZH<C@\G'_  *O>JX7Q=\-X_$^MQZK!J9L)U15
M?;!OW%3PV=PP<8'X"NWA61((UED$DBJ [A=H8XY..WTJ:DE*S6Y4$XZ#Z\U\
M?>&?!^D:;<:S<Z?MNG.V*&*5D660]. >!W.,<#UKTJN&\7_#ZX\7ZM%<W&N&
M"UA4+';+;;MH_B.[?U/KCL/2IINTM78<U=;'(?"3PC]KNSXBO(_W,#%;53_$
M_=OH.@]_I5WXO:?K>IZEIT%A8WUU:1PER+>!G4.21S@=< ?Y->IV-E;Z=8P6
M5K&(X($"(H[ 58JG5?/S$^S7+RGA>I^*/&9\+S:7<>%Q9Z:(/*9Q83H(T''5
MFP/QI_PPUSQ!9O!IMCI7GZ5/>YN+K[/(WEDA0?G!VC  /([U[!KNE_VWH5YI
MGG>3]IC,?F;=VW/?&1G\ZS?!?A7_ (1#1YM/^V_:_,N#/YGE>7C*JN,9/]W]
M:KVD>5JPN1\VYT=>+ZA_R<"G_7>'_P!$+7M%<7<> ?/^((\5?VGMPZ/]F\C/
MW4"?>W>V>E13DE>_8J:;M8[-FVJ6()P,\#)KD]'^(_A_6M6?3X)I(9 N4>X4
M1K(>X&3U^N*ZVO/_ !'\)]*UN^DO;2YDT^>4[I B!XV;N=N1@GV-*'+]H<N;
MH4OC!JVEOX<BT_SHIKYIU>-$8%HP <L?0=OQ]J<L6H:?\!]D9=;G[(7/8B-Y
M,G_QQC4NA_!_2--NDN-0NY-19#E8V01QD^XR2?IG%>AO%')$T3HK1LNTH1P1
MZ8]*MRBDDM25%MML\T^#U]I$?A^>W$D,6H^<S2AV =UP-I'J!_/-<W\2;ZTG
M\>:?)H3QOJ$>P/)"009=_P H)'4CO^ KI=5^#&EW=R\NG:C-8JQSY31B55^G
M(./J36MX7^&&D>'+U+YYI;V\CYC>0!50^H4=_J35<\%)SN3RR:Y3MZ***YS8
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N-^)T6I7'@V2WTN"YFEFF1)([>,NQ3DG@<XR!FNRHIQ=G<35U8
M\*\.:SXW\+Z7]@T_PE(4+EWDET^<NY/J00.F!T[5A^%];U_3/$U]>Z3I?VO4
M)4D6:#[/))L!=2QVJ<C! '/K7TC7%^%_ /\ PC?B:^UG^T_M'VI)$\GR-FW<
MZMUW'.-N.E;JK&SNC)TWI9G66$LT^G6LUQ'Y<\D2-(FTC:Q )&#R.:\J^./_
M # ?^WC_ -IUZ[7(>./ _P#PF?V#_B8_8_LGF?\ +#S-^[;_ +0QC;^M9TY)
M3NRYIN-D=+IG_(*L_P#K@G_H(KG=4^(FA:/KZZ/=M.DX<+)(8\1QY&023VY'
M(%=/;0_9[2&#=N\M%3=C&<#%<WXL\!Z5XMV37!>WO(QM6XBQDCT8'J*F/+?W
MAN]M"QXIUO1[3PO?/>75O)#+;NBQAP3*2"  .^:XOX)6TR:=JUTV?)EEC1,C
MC*ABW_H2TMG\$K*.X#7NLSSQ YV10B,GVR2W\J]*T[3K32K"*RL8%AMXEPB+
M_GD^]6W&,>6.MR4I.5V5?^$CT;^V/[(_M&W_ +0Z>1N^;/7'IGVZU9U+2['6
M+)[/4+:.XMWZHX_4'J#[BN1_X5G8_P#";?\ "1?;9MOG_:?LVW_EIG.=V>F>
M<8_&NUG65[>18)%CE*D([+N"G'!(R,_3(J'96Y64KO<\ \?Z1H&DZO#HN@6L
MKWNX><WFL^TG[L:CUYR?P]Z]>\#^%H_"OA^.V8*;R;]Y<N.<OZ ^@Z?F>]8_
MAOX9Q:+XB;6K_5&U*YRSKO@V8D;JY^8Y/7\Z[VM*D[I13)A"SNRIJFHP:1I=
MSJ%RV(;>,NWOCL/<]/QKQ[X:Z=<>*/&EYXDU ;UMW,N2.#*WW0/91GZ?+7I?
MC'PU/XKTA=-CU'[%$9 \I\GS-^.@^\,#//X"IO"GAN#PKH4>FPR><P8O),4V
MF1CWQDXXP.O:IC)1@[;L;3<EV-NO#OAO?VD/CS49=>DC349-X228@ 2[_F&3
MT)[?B*]QKB/%'PPTCQ'>O?)-+97DG,CQ@,KGU*GO]"**<DKI]0FF[-&/\8;[
M2)/#\%N9()=1\Y6B","Z+@[B?0'^>/2NI\ RSGP!I,M\V'$!^9CC"!CM)_X#
MBN8TKX,:7:7*2ZCJ,U\JG/E+&(E;Z\DX^A%>B7%C!<Z;+I[)MMY83"53Y<(1
MC ].*<G'E44**=^9E;2_$&D:V\R:;J$%RT/WQ&W(]_I[UI5QO@WX>VOA"^NK
MQ+V2ZFF3REW($")D''4Y.0.>.G2NRJ)6O[I<;VU/%_!O_):M9_Z[W?\ Z,->
MR3SQ6MO+<3R+'#$A=W8\*H&23^%<?HW@'^R/&MYXB_M/S?M+S/\ 9_(V[?,;
M/WMQSCZ5U&K6/]J:/?:?YGE?:K>2#S-N[;N4KG'?&:JHU)HF":1X]XC\2ZK\
M1M970O#T<BZ<#\S<KY@_OR>BCL/ZX ])\(>#;#PEI_EP@2WD@'GW)'+'T'HO
MM7#?\*._ZF+_ ,DO_ME'_"CO^IB_\DO_ +96DG!KE4K(A*2=VCM?B)ILFJ>!
MM2AA4M+&@F4 9)V$,?T!KG?A'XALY?#7]D37"1W5K(Q5';&Y&.[(S[DY_P#K
MUWVE6/\ 9FC6.G^9YOV6WC@W[<;MJA<XYQG'2N#USX/:7J-Y)<Z?>R:>9&W-
M$(A)&#_LC((^F:B+CR\K*DG?F1S/Q,U&/Q3XPTS1=+D6<P_NMR'<OF.PST]
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M2?SKI_%OAS_A*- ?2_M7V7<ZOYGE[\8.<8R/YU#FN9:C479Z&9\+E ^'>ED
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RK5?A-J"ZK-J.AZ])%-*S.?/9E<$G)^=>
M3S[?G4,/PGUO4[J.3Q)XA,\:'HDCS,1Z!GQC\C7K=%:>UD1[.)7L;*WTVQ@L
MK2,1V\"!(T'8"K%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
